| Master Investor Magazine
|
AIM-listed pharmaceutical business Summit Therapeutics (LON:SUMM) has seen its share price rise by 9.80% to 28p (as of 15:30 BST) after its Ridinilazole treatment was found to improve short and longer term quality of life measurements for patients with C. difficile infections. The results from a phase 2 clinical trial were presented at a conference in Washington this month.
Chief Commercial Officer Dr. David Elger commented: “The patient is at the centre of our drug development universe. Global regulatory authorities and payors recognise that the value of treatments encompasses more than just clinical results and are placing increasing importance on patient reported outcomes, such as the EQ-5D index, in assessing new therapies. We are highly encouraged by the early and significant changes seen in the Phase 2 trial for patients on ridinilazole compared to the current standard of care, vancomycin, and look forward to the data from patient reported outcomes in our ongoing Phase 3 clinical trials of ridinilazole“.